RegulatoryCompany release

Kyverna completes rolling BLA for miv-cel CAR-T in stiff person syndrome

🇺🇸 Kyverna Therapeutics, Inc. (KYTX) · Thu 12 Nov 2026

The US biotech has finished its FDA submission for the CAR-T therapy and is seeking priority review, with a potential 2027 launch.

Kyverna Therapeutics has completed its rolling Biologics License Application (BLA) to the US Food and Drug Administration for miv-cel (mivocabtagene autoleucel, also known as KYV-101) in stiff person syndrome. The company is asking the agency for priority review and points to the therapy's Regenerative Medicine Advanced Therapy (RMAT) designation in support of that request.

The application is based on the KYSA-8 registrational trial. Kyverna says it is planning for a potential commercial launch in 2027. The source material available does not include further detail on the trial results or the FDA's filing decision, so neither is covered here.

As context, a rolling submission lets a sponsor send completed sections of an application for FDA review as they become ready, rather than waiting to file the whole dossier at once. Priority review is an FDA designation that aims for a shorter review clock than standard review.

Kyverna disclosed the filing alongside its third-quarter 2026 results on 12 November 2026. It reported cash of $170.6 million and a net loss of $41.9 million for the period. The company expects enrolment in KYSA-6, its myasthenia gravis (gMG) study, to finish in mid-2027. It also said it is deprioritising KYV-102.

What it means for your team

  • Regulatory teams should watch for the FDA's acceptance of the BLA and its decision on priority review, which will shape the likely approval timeline.
  • Market-access and launch planners tracking autoimmune cell therapy should note the company's stated potential 2027 launch in stiff person syndrome.
  • Teams following the CAR-T pipeline in autoimmune disease should note that the gMG trial, KYSA-6, is not expected to complete enrolment until mid-2027.

Company's press release (SEC filing): Kyverna Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Kyverna Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →